细胞毒性T淋巴细胞相关抗原4 Ig和anti—CD154单抗在移植中的研究进展  

Progress of researches on CTLA-4 Ig and anti-CD154mAb in organ transplantation

作　　者：夏婷[1] 方建培[1] 

机构地区：[1]中山大学第二附属医院儿科,广州510120

出　　处：《国际免疫学杂志》2012年第4期245-248,共4页International Journal of Immunology

基　　金：高等学校博士学科点专项科研基金（20090171110064）

摘　　要：细胞毒性T淋巴细胞相关抗原（CTLA）-4 Ig和anti—CD154单抗是目前器官移植的新型生物免疫抑制剂。两者均通过阻断协同刺激信号来抑制T淋巴细胞的活化，从而起到免疫耐受作用，在器官移植中有很好的应用前景。CTLA-4 Ig和anti—CD154单抗在动物模型实验中研究发现单用或联用有长久强效的免疫耐受作用能延长移植物的存活期。在临床中的应用尚处于初期，其临床副作用、安全性及长期的疗效有待进一步观察。CTLA-4 Ig and anti-CD154mAb （anti-CD154 monoclonal antibody） are the two novel biological immune inhibitors in the organ transplantation. They inhibit T lymphocyte activation by blocking co-stimulatory signal pathways, and playing an immune tolerance role in organ transplantation. Therefore, they would have a good application prospect in transplant tolerance. CTLA-4 Ig and anti-CD154mAb have been proved to be highly effective in immune tolerance by single or combined application, which can prolong transplant survival in various animal transplantation models. The clinical application is still in the initial stage, while their clinical side effects, safety and long-term efficacy need further observation. This review summarizes the two inbibitors＇ immunological characters, the mechanisms of their functions and their application in organ transplantation.

关 键 词：细胞毒性T淋巴细胞相关抗原4 IG anti—CD154单抗 协同刺激信号 移植 

分 类 号：R392[医药卫生—免疫学]